West of Scotland Cancer Network Skin Cancer MCN Work Plan 2023/2024

	Actions Required	Lead	Due Date
1.	Continue to engage with the Regional MDT Improvement Programme to optimise operational efficiency and effect	ctiveness of the MDT	
1.1	Work with MDT programme Board and eHealth colleagues to progress development of the MDT system ready for regional implementation, utilising the agreed core dataset for skin cancers.	MDT-FIT Project Facilitator MCN Clinical Lead	Ongoing
1.2	Agree actions arising from the MDT-FIT QA process and engage with local MDTs to deliver against these.	MCN&I Manager Local MDT Leads and members	Ongoing
2. C	ptimise patient pathways for patients with non-melanoma skin cancer		
2.1.1	Monitor progress against actions identified from the pilot project in NHSGGC undertaken in partnership with pharma (Sanofi).	MCN Clinical Lead MCN&I Manager	Ongoing
2.1.2	Following information gathering exercise with key stakeholders in NHSAA, NHSFV and NHS Lan, facilitate local Board meetings to discuss findings, identify then prioritise potential solutions to current challenges, optimise the cutaneous squamous cell carcinoma (cSCC) pathway and agree actions.	MCN Clinical Lead MCN&I Manager MCN Clinicians	Aug 23
2.1.3	 Facilitate implementation of revised cSCC pathway. Identify common potential points of redesign/improvement and facilitate regional workstreams to progress Work in collaboration with local teams to identify any specific service changes/pathway redesign 	MCN Clinical Lead MCN&I Manager MCN Clinicians	Nov 23
2.2.1	 Establish regional clinic/MDT for complex Basal Cell Carcinoma (BCC) cases Conclude the development of a regional CMG for BCC (see 5.1) and agree the clinical pathway for complex cases Agree location, timing and membership of regional BCC clinic/MDT (Terms of Reference) Agree clinical support with relevant specialties 	MCN Clinical Lead MCN&I Manager MCN Clinicians	Aug 23
3. C	onclude the review of national/regional skin cancer follow-up guidelines and incorporate a risk stratified approac	h	
3.1	Co-ordinate the review of follow-up guidance in line with WoSCAN SOP. • Squamous Cell Carcinoma (National) • Basal Cell Carcinoma (Regional)	MCN Clinical Lead MCN&I Manager Advisory Board	Jun 23 Aug 23
3.2	Facilitate regional implementation of revised pathways. • Work in collaboration with local teams to identify any specific operational and service changes required to facilitate regional implementation of the revised follow-up guidance	MCN Clinical Lead MCN&I Manager Advisory Board	Aug 23

	Actions Required	Lead	Due Date
			Nov 23
3.3	Develop information, rollout, and local implementation tools, for use by NHS Boards as required within the WoS.	MCN Clinical Lead MCN&I Manager	Sep 23 Dec 23
4.	Undertake a review of the Regional Skin Cancer MDT in light of new guidelines and potential changes in adjuvar	_	30023
4.1	Consider the impact of new guidelines and anticipated therapeutic and imaging changes	MCN Clinical Lead MCN&I Manager Regional MDT Chair	Jun 23
4.2	Review membership and timing of Regional MDT to facilitate accurate and appropriate discussion of these patients	MCN Clinical Lead MCN&I Manager Regional MDT Chair	Jun 23
4.3	Link with clinicians/services to discuss job planning	MCN Clinical Lead Regional MDT Chair MCN Clinicians	Aug 23
5.	Formally establish the skin specialist nurses group as an independent subgroup of the Skin Cancer MCN		
5.1	Agree Terms of Reference, meeting schedules and reporting mechanisms	MCN Clinical Lead MCN&I Manager Nurses Subgroup	Jun 23
5.2	Agree timescales for progressing initial workstreams: Role/timing of Holistic Needs Assessment (HNA) as per new melanoma national follow-up guideline Standardisation of patient information	MCN Clinical Lead MCN&I Manager Nurses Subgroup	TBC
6.	Support audit and research to generate data and outcomes to improve patient pathways		1
6.1	 The Skin Cancer MCN Research Group to continue to: Identify areas where there is currently a lack of clinical evidence to support practice Support groups from all interested specialties in obtaining appropriate data to generate suitable analysis e.g. follow-up of melanoma imaging Where appropriate, encourage regional collaboration on projects to achieve patient numbers and standardise outcomes in cancer care across the network 	MCN Research Group MCN&I Manager Information Analyst	Mar 24
7.	Develop and maintain regional /national clinical guidelines to optimise patient care		
7.1	Co-ordinate the review of clinical management guidelines in line with WoSCAN SOP. CMGs National SCC CMG (new) Basal Cell Carcinoma (new)	MCN Clinical Lead MCN&I Manager WoSCAN Clinicians	Apr 23 Aug 23

	Actions Required	Lead	Due Date	
	Ano-Uro-Genital Malignant Melanoma		Aug 23	
	CGDs			
	Transplant Recipients at Risk of Skin Cancer Surveillance Guidelines		Sep 23	
	Identification of Correct Site for Further Surgery or Radiotherapy		Sep 23	
8.	Maintain regional service configuration map for skin cancers			
8.1	Update activity data.	MCN&I Manager	Jun 23	
		Information Analyst		
8.2	Refresh as per any changes in configuration.	MCN&I Manager	Mar 24	
9.	9. Deliver regional education event which facilitates review of clinical audit data, as required, and promotes shared learning of current best practice and innovation			
9.1	Develop a focused programme for the event, addressing relevant key issues.	MCN Clinical Lead MCN&I Manager	Apr 23	
9.2	Establish data requirements for the event, and identify any arising from the event.	MCN Clinical Lead	Apr 23	
	Liaise with information team regards audit presentation requirements	MCN&I Manager		
	Liaise with information team if any further audit opportunities identified	Information Team	Jun 23	
	Ensure appropriate data sharing agreements issued, completed, agreed and passed to Information Team			
9.3	Develop action plans arising from event and monitor progress of agreed actions.	MCN Clinical Lead	July 23	
	Record actions arising from discussion at event	MCN&I Manager		
	Develop action plans of same			
	Issue action plans as appropriate			
	Monitor progress of actions recorded			
10.	Use clinical data to drive improvement in quality of care and outcomes			
10.1	Review QPI audit findings to identify variation in practice and highlight exceptions.	MCN Clinical Lead	Jan 24	
	Performance Summary Returns Assessed	MCN&I Manager		
	RCOG exception report produced	Information		
	Governance review and Interrogation of QPI exceptions	Manager		
	Agreement of actions for inclusion in annual audit reports	Information Analyst		
	Input to the production of Annual Audit Report			

	Actions Required	Lead	Due Date
10.2	 Identify requirements for further data analysis to aid understanding of variance, and develop action/improvement plan. Targeted assessment of effectiveness of actions undertaken in the individual WoS Boards to improve performance against QPI 4 (Clinical Examination of Draining Lymph Node Basins) Coordinate regional discussion with radiology services on the patient pathway for CT imaging in light of performance against QPI 9, the recent publication of the national follow-up guideline and the approval of new adjuvant regimens. 	MCN Clinical Lead MCN&I Manager WoSCAN Clinicians Information Analyst	
10.3	Monitor and ensure progress with regional and local board action/improvement plans. • Conclusion of actions from QPI Exception Report	MCN Clinical Lead MCN&I Manager Board Clinical Effectiveness Leads	Mar 24
10.4	Contribute to the national Melanoma QPI formal review process, ensuring appropriate engagement across all specialties. • Engage with wide MCN for feedback on potential changes to existing QPIs and suggestions for new QPIs • Review MCN feedback and consider refinements • Engage with Skin Cancer Clinical Leads in SCAN and NCA in advance of review meeting regarding any proposed changes	MCN Clinical Lead MCN&I Manager Advisory Board	Nov 23 Dec 23 Jan 23
11.	Watching brief and development as required on the following work streams		_
11.1	Maintain watching brief on the development of a national digital solution for Treatment Summaries, and provide input or support where requested	Designated Clinical Lead MCN&I Manager	ТВС
11.2	Maintain watching brief on the roll out of the Regional prehabilitation workstream in line with the actions outlined in the WoSCAN Regional Delivery Plan for Best Preparation for Treatment (Pre-treatment), and provide input or support where requested.	Designated Clinical Lead MCN&I Manager	TBC
11.3	Maintain watching brief on roll out of Regional PROMS workstream in line with the actions outlined in the WoSCAN Regional Delivery Plan for Person Centred Care for All, and provide input or support where requested.	Designated Clinical Lead MCN&I Manager	TBC
11.4	Horizon Scanning – actively seek from the MCN membership significant changes in guidelines/therapeutic advances and engage with the relevant clinicians/services to consider the impact in a proactive manner.	MCN Clinical Lead MCN&I Manager Advisory Board	TBC